Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis
Abstract Background The aim of this study was to assess the efficacy, tolerability and safety of risedronate in adults with CF. Methods Patients with a lumbar spine (LS), total hip (TH) or femoral neck (FN) bone mineral density (BMD) Z-score of − 1 or less were randomised to receive risedronate 35 m...
Gespeichert in:
| Veröffentlicht in: | Journal of cystic fibrosis 2011-12, Vol.10 (6), p.470-476 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 476 |
|---|---|
| container_issue | 6 |
| container_start_page | 470 |
| container_title | Journal of cystic fibrosis |
| container_volume | 10 |
| creator | Haworth, Charles S Sharples, Linda Hughes, Vikki Elkin, Sarah L Hodson, Margaret E Conway, Steven P Etherington, Christine Elborn, J. Stuart Rendall, Jackie Wheaton, Ella Kadri, Emma Elliott, Jane Barker, Helen C Bearcroft, Philip W.P Hlaing, Thinn Compston, Juliet E |
| description | Abstract Background The aim of this study was to assess the efficacy, tolerability and safety of risedronate in adults with CF. Methods Patients with a lumbar spine (LS), total hip (TH) or femoral neck (FN) bone mineral density (BMD) Z-score of − 1 or less were randomised to receive risedronate 35 mg weekly or placebo, and calcium (1 g) + vitamin D3 (800 IU). Results At baseline, BMD Z-scores in the risedronate (n = 17) and placebo (n = 19) groups were similar. By 24 months, 7/17 risedronate patients vs 0/19 placebo patients stopped the study medication due to bone pain. After 24 months treatment, the mean difference (95% CI) in change in LS, TH and FN BMD between the risedronate vs placebo groups was 4.3% (0.4, 8.2) p = 0.03; 4.0% (− 0.5, 8.6) p = 0.08; and 2.4% (-3.5, 8.2) p = 0.41. Conclusions After two years treatment there was a significant increase in LS BMD with weekly risedronate compared to placebo. |
| doi_str_mv | 10.1016/j.jcf.2011.07.007 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_905682810</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1569199311001305</els_id><sourcerecordid>905682810</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-8176256c9466562a5610ec9e6bbd4f6fd6ad3f8185299dcebe4e1b748bbe11f33</originalsourceid><addsrcrecordid>eNp9kUtv1TAQhS0EoqXwA9gg71glzOTh2EJCQhUvqYgFj62V2BPhNNcuttMq_x5f3cKCBauZxTlHM99h7DlCjYDi1VIvZq4bQKxhqAGGB-wc5dBWPSA8LHsvVIVKtWfsSUoLAA4wyMfsrEHZqUZ05-zH523NzpDPkXiOblx5mPkd0fW68-gS2Rj8mIkHz6fgiVvyyeWdO89HW7yJ37n8k5s9lRg-uymG5NJT9mge10TP7ucF-_7-3bfLj9XVlw-fLt9eVabrIVcSB9H0wqhOiF40Yy8QyCgS02S7WcxWjLadJcq-UcoamqgjnIZOThMhzm17wV6ecm9i-LVRyvrgkqF1HT2FLWkFvZCNRChKPClNOTBFmvVNdIcx7hpBH2nqRRea-khTw6ALzeJ5cZ--TQeyfx1_8BXB65OAyo-3jqJOxpE3ZF0kk7UN7r_xb_5xm9V5Z8b1mnZKS9iiL_A06tRo0F-PdR7bRCxNttC3vwGVwprS</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>905682810</pqid></control><display><type>article</type><title>Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Haworth, Charles S ; Sharples, Linda ; Hughes, Vikki ; Elkin, Sarah L ; Hodson, Margaret E ; Conway, Steven P ; Etherington, Christine ; Elborn, J. Stuart ; Rendall, Jackie ; Wheaton, Ella ; Kadri, Emma ; Elliott, Jane ; Barker, Helen C ; Bearcroft, Philip W.P ; Hlaing, Thinn ; Compston, Juliet E</creator><creatorcontrib>Haworth, Charles S ; Sharples, Linda ; Hughes, Vikki ; Elkin, Sarah L ; Hodson, Margaret E ; Conway, Steven P ; Etherington, Christine ; Elborn, J. Stuart ; Rendall, Jackie ; Wheaton, Ella ; Kadri, Emma ; Elliott, Jane ; Barker, Helen C ; Bearcroft, Philip W.P ; Hlaing, Thinn ; Compston, Juliet E</creatorcontrib><description>Abstract Background The aim of this study was to assess the efficacy, tolerability and safety of risedronate in adults with CF. Methods Patients with a lumbar spine (LS), total hip (TH) or femoral neck (FN) bone mineral density (BMD) Z-score of − 1 or less were randomised to receive risedronate 35 mg weekly or placebo, and calcium (1 g) + vitamin D3 (800 IU). Results At baseline, BMD Z-scores in the risedronate (n = 17) and placebo (n = 19) groups were similar. By 24 months, 7/17 risedronate patients vs 0/19 placebo patients stopped the study medication due to bone pain. After 24 months treatment, the mean difference (95% CI) in change in LS, TH and FN BMD between the risedronate vs placebo groups was 4.3% (0.4, 8.2) p = 0.03; 4.0% (− 0.5, 8.6) p = 0.08; and 2.4% (-3.5, 8.2) p = 0.41. Conclusions After two years treatment there was a significant increase in LS BMD with weekly risedronate compared to placebo.</description><identifier>ISSN: 1569-1993</identifier><identifier>EISSN: 1873-5010</identifier><identifier>DOI: 10.1016/j.jcf.2011.07.007</identifier><identifier>PMID: 21849264</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adult ; Bone Density - drug effects ; Bone Density Conservation Agents - administration & dosage ; Bone Density Conservation Agents - pharmacology ; Bone mineral density ; Cystic Fibrosis ; Drug Administration Schedule ; Etidronic Acid - administration & dosage ; Etidronic Acid - analogs & derivatives ; Etidronic Acid - pharmacology ; Female ; Fractures ; Humans ; Male ; Osteoporosis ; Pulmonary/Respiratory ; Risedronic Acid ; Single-Blind Method</subject><ispartof>Journal of cystic fibrosis, 2011-12, Vol.10 (6), p.470-476</ispartof><rights>European Cystic Fibrosis Society</rights><rights>2011 European Cystic Fibrosis Society</rights><rights>Copyright © 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c450t-8176256c9466562a5610ec9e6bbd4f6fd6ad3f8185299dcebe4e1b748bbe11f33</citedby><cites>FETCH-LOGICAL-c450t-8176256c9466562a5610ec9e6bbd4f6fd6ad3f8185299dcebe4e1b748bbe11f33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jcf.2011.07.007$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3548,27922,27923,45993</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21849264$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Haworth, Charles S</creatorcontrib><creatorcontrib>Sharples, Linda</creatorcontrib><creatorcontrib>Hughes, Vikki</creatorcontrib><creatorcontrib>Elkin, Sarah L</creatorcontrib><creatorcontrib>Hodson, Margaret E</creatorcontrib><creatorcontrib>Conway, Steven P</creatorcontrib><creatorcontrib>Etherington, Christine</creatorcontrib><creatorcontrib>Elborn, J. Stuart</creatorcontrib><creatorcontrib>Rendall, Jackie</creatorcontrib><creatorcontrib>Wheaton, Ella</creatorcontrib><creatorcontrib>Kadri, Emma</creatorcontrib><creatorcontrib>Elliott, Jane</creatorcontrib><creatorcontrib>Barker, Helen C</creatorcontrib><creatorcontrib>Bearcroft, Philip W.P</creatorcontrib><creatorcontrib>Hlaing, Thinn</creatorcontrib><creatorcontrib>Compston, Juliet E</creatorcontrib><title>Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis</title><title>Journal of cystic fibrosis</title><addtitle>J Cyst Fibros</addtitle><description>Abstract Background The aim of this study was to assess the efficacy, tolerability and safety of risedronate in adults with CF. Methods Patients with a lumbar spine (LS), total hip (TH) or femoral neck (FN) bone mineral density (BMD) Z-score of − 1 or less were randomised to receive risedronate 35 mg weekly or placebo, and calcium (1 g) + vitamin D3 (800 IU). Results At baseline, BMD Z-scores in the risedronate (n = 17) and placebo (n = 19) groups were similar. By 24 months, 7/17 risedronate patients vs 0/19 placebo patients stopped the study medication due to bone pain. After 24 months treatment, the mean difference (95% CI) in change in LS, TH and FN BMD between the risedronate vs placebo groups was 4.3% (0.4, 8.2) p = 0.03; 4.0% (− 0.5, 8.6) p = 0.08; and 2.4% (-3.5, 8.2) p = 0.41. Conclusions After two years treatment there was a significant increase in LS BMD with weekly risedronate compared to placebo.</description><subject>Adult</subject><subject>Bone Density - drug effects</subject><subject>Bone Density Conservation Agents - administration & dosage</subject><subject>Bone Density Conservation Agents - pharmacology</subject><subject>Bone mineral density</subject><subject>Cystic Fibrosis</subject><subject>Drug Administration Schedule</subject><subject>Etidronic Acid - administration & dosage</subject><subject>Etidronic Acid - analogs & derivatives</subject><subject>Etidronic Acid - pharmacology</subject><subject>Female</subject><subject>Fractures</subject><subject>Humans</subject><subject>Male</subject><subject>Osteoporosis</subject><subject>Pulmonary/Respiratory</subject><subject>Risedronic Acid</subject><subject>Single-Blind Method</subject><issn>1569-1993</issn><issn>1873-5010</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUtv1TAQhS0EoqXwA9gg71glzOTh2EJCQhUvqYgFj62V2BPhNNcuttMq_x5f3cKCBauZxTlHM99h7DlCjYDi1VIvZq4bQKxhqAGGB-wc5dBWPSA8LHsvVIVKtWfsSUoLAA4wyMfsrEHZqUZ05-zH523NzpDPkXiOblx5mPkd0fW68-gS2Rj8mIkHz6fgiVvyyeWdO89HW7yJ37n8k5s9lRg-uymG5NJT9mge10TP7ucF-_7-3bfLj9XVlw-fLt9eVabrIVcSB9H0wqhOiF40Yy8QyCgS02S7WcxWjLadJcq-UcoamqgjnIZOThMhzm17wV6ecm9i-LVRyvrgkqF1HT2FLWkFvZCNRChKPClNOTBFmvVNdIcx7hpBH2nqRRea-khTw6ALzeJ5cZ--TQeyfx1_8BXB65OAyo-3jqJOxpE3ZF0kk7UN7r_xb_5xm9V5Z8b1mnZKS9iiL_A06tRo0F-PdR7bRCxNttC3vwGVwprS</recordid><startdate>20111201</startdate><enddate>20111201</enddate><creator>Haworth, Charles S</creator><creator>Sharples, Linda</creator><creator>Hughes, Vikki</creator><creator>Elkin, Sarah L</creator><creator>Hodson, Margaret E</creator><creator>Conway, Steven P</creator><creator>Etherington, Christine</creator><creator>Elborn, J. Stuart</creator><creator>Rendall, Jackie</creator><creator>Wheaton, Ella</creator><creator>Kadri, Emma</creator><creator>Elliott, Jane</creator><creator>Barker, Helen C</creator><creator>Bearcroft, Philip W.P</creator><creator>Hlaing, Thinn</creator><creator>Compston, Juliet E</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20111201</creationdate><title>Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis</title><author>Haworth, Charles S ; Sharples, Linda ; Hughes, Vikki ; Elkin, Sarah L ; Hodson, Margaret E ; Conway, Steven P ; Etherington, Christine ; Elborn, J. Stuart ; Rendall, Jackie ; Wheaton, Ella ; Kadri, Emma ; Elliott, Jane ; Barker, Helen C ; Bearcroft, Philip W.P ; Hlaing, Thinn ; Compston, Juliet E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-8176256c9466562a5610ec9e6bbd4f6fd6ad3f8185299dcebe4e1b748bbe11f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Bone Density - drug effects</topic><topic>Bone Density Conservation Agents - administration & dosage</topic><topic>Bone Density Conservation Agents - pharmacology</topic><topic>Bone mineral density</topic><topic>Cystic Fibrosis</topic><topic>Drug Administration Schedule</topic><topic>Etidronic Acid - administration & dosage</topic><topic>Etidronic Acid - analogs & derivatives</topic><topic>Etidronic Acid - pharmacology</topic><topic>Female</topic><topic>Fractures</topic><topic>Humans</topic><topic>Male</topic><topic>Osteoporosis</topic><topic>Pulmonary/Respiratory</topic><topic>Risedronic Acid</topic><topic>Single-Blind Method</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Haworth, Charles S</creatorcontrib><creatorcontrib>Sharples, Linda</creatorcontrib><creatorcontrib>Hughes, Vikki</creatorcontrib><creatorcontrib>Elkin, Sarah L</creatorcontrib><creatorcontrib>Hodson, Margaret E</creatorcontrib><creatorcontrib>Conway, Steven P</creatorcontrib><creatorcontrib>Etherington, Christine</creatorcontrib><creatorcontrib>Elborn, J. Stuart</creatorcontrib><creatorcontrib>Rendall, Jackie</creatorcontrib><creatorcontrib>Wheaton, Ella</creatorcontrib><creatorcontrib>Kadri, Emma</creatorcontrib><creatorcontrib>Elliott, Jane</creatorcontrib><creatorcontrib>Barker, Helen C</creatorcontrib><creatorcontrib>Bearcroft, Philip W.P</creatorcontrib><creatorcontrib>Hlaing, Thinn</creatorcontrib><creatorcontrib>Compston, Juliet E</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cystic fibrosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Haworth, Charles S</au><au>Sharples, Linda</au><au>Hughes, Vikki</au><au>Elkin, Sarah L</au><au>Hodson, Margaret E</au><au>Conway, Steven P</au><au>Etherington, Christine</au><au>Elborn, J. Stuart</au><au>Rendall, Jackie</au><au>Wheaton, Ella</au><au>Kadri, Emma</au><au>Elliott, Jane</au><au>Barker, Helen C</au><au>Bearcroft, Philip W.P</au><au>Hlaing, Thinn</au><au>Compston, Juliet E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis</atitle><jtitle>Journal of cystic fibrosis</jtitle><addtitle>J Cyst Fibros</addtitle><date>2011-12-01</date><risdate>2011</risdate><volume>10</volume><issue>6</issue><spage>470</spage><epage>476</epage><pages>470-476</pages><issn>1569-1993</issn><eissn>1873-5010</eissn><abstract>Abstract Background The aim of this study was to assess the efficacy, tolerability and safety of risedronate in adults with CF. Methods Patients with a lumbar spine (LS), total hip (TH) or femoral neck (FN) bone mineral density (BMD) Z-score of − 1 or less were randomised to receive risedronate 35 mg weekly or placebo, and calcium (1 g) + vitamin D3 (800 IU). Results At baseline, BMD Z-scores in the risedronate (n = 17) and placebo (n = 19) groups were similar. By 24 months, 7/17 risedronate patients vs 0/19 placebo patients stopped the study medication due to bone pain. After 24 months treatment, the mean difference (95% CI) in change in LS, TH and FN BMD between the risedronate vs placebo groups was 4.3% (0.4, 8.2) p = 0.03; 4.0% (− 0.5, 8.6) p = 0.08; and 2.4% (-3.5, 8.2) p = 0.41. Conclusions After two years treatment there was a significant increase in LS BMD with weekly risedronate compared to placebo.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>21849264</pmid><doi>10.1016/j.jcf.2011.07.007</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1569-1993 |
| ispartof | Journal of cystic fibrosis, 2011-12, Vol.10 (6), p.470-476 |
| issn | 1569-1993 1873-5010 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_905682810 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present); EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Bone Density - drug effects Bone Density Conservation Agents - administration & dosage Bone Density Conservation Agents - pharmacology Bone mineral density Cystic Fibrosis Drug Administration Schedule Etidronic Acid - administration & dosage Etidronic Acid - analogs & derivatives Etidronic Acid - pharmacology Female Fractures Humans Male Osteoporosis Pulmonary/Respiratory Risedronic Acid Single-Blind Method |
| title | Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T22%3A21%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multicentre%20trial%20of%20weekly%20risedronate%20on%20bone%20density%20in%20adults%20with%20cystic%20fibrosis&rft.jtitle=Journal%20of%20cystic%20fibrosis&rft.au=Haworth,%20Charles%20S&rft.date=2011-12-01&rft.volume=10&rft.issue=6&rft.spage=470&rft.epage=476&rft.pages=470-476&rft.issn=1569-1993&rft.eissn=1873-5010&rft_id=info:doi/10.1016/j.jcf.2011.07.007&rft_dat=%3Cproquest_cross%3E905682810%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=905682810&rft_id=info:pmid/21849264&rft_els_id=1_s2_0_S1569199311001305&rfr_iscdi=true |